Last 7 days
-0.8%
Last 30 days
-10.2%
Last 90 days
0.3%
Trailing 12 Months
307.7%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
BGNE | 311.1B | 1.6B | -10.47% | 70.40% | -162.26 | 199.76 | 77.54% | 1.62% |
ABBV | 285.4B | 56.7B | -9.71% | -7.25% | 24.12 | 4.92 | 0.03% | -39.22% |
REGN | 87.6B | 12.4B | -9.13% | 5.17% | 20.2 | 7.2 | -25.07% | -47.28% |
VRTX | 83.8B | 9.2B | -4.53% | 18.84% | 25.7 | 9.1 | 15.86% | 32.99% |
ALNY | 23.2B | 1.0B | -6.40% | 45.93% | -21.75 | 22.33 | 22.88% | -19.27% |
SRPT | 11.6B | 975.7M | 1.67% | 67.21% | -10.42 | 11.92 | 27.41% | -212.78% |
UTHR | 9.6B | 2.0B | -10.84% | -12.99% | 13.17 | 4.84 | 12.05% | 52.86% |
MID-CAP | ||||||||
MDGL | 5.1B | - | -10.25% | 307.66% | -16.27 | 2.5K | - | -27.52% |
BPMC | 3.4B | 204.6M | 10.50% | 0.21% | -5.87 | 16.66 | -7.52% | 10.65% |
RARE | 3.4B | 363.3M | 10.85% | -0.47% | -4.8 | 9.35 | 3.39% | -55.81% |
MRTX | 2.2B | 18.9M | -16.27% | -6.81% | -2.93 | 114.18 | - | -16.17% |
SMALL-CAP | ||||||||
CYTK | 3.6B | - | 1.50% | -9.34% | -8.36 | 38.06 | 34.30% | -67.22% |
CPRX | 1.2B | 256.5M | -27.45% | 57.57% | 12.31 | 4.77 | 66.85% | 120.61% |
MGNX | 288.8M | 165.3M | -32.22% | 33.43% | -3.16 | 1.75 | 130.70% | 57.97% |
CRBP | 37.4M | - | 1.03% | 2894.60% | -0.74 | 19.11 | - | -29.84% |
Income Statement (Last 12 Months) | ||||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 |
Revenue | -51.1% | 363,000 | 743,000 | 1,506,000 | 2,619,000 | 4,329,000 |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Assets | -8.3% | 332 | 363 | 159 | 216 | 223 |
Current Assets | -8.3% | 331 | 361 | 157 | 215 | 221 |
Cash Equivalents | -65.8% | 113 | 332 | 59.00 | 53.00 | 42.00 |
Net PPE | -14.8% | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
Liabilities | 10.4% | 182 | 165 | 148 | 133 | 77.00 |
Current Liabilities | -15.1% | 98.00 | 116 | 99.00 | 84.00 | 77.00 |
Long Term Debt | - | 67.00 | - | - | - | - |
LT Debt, Non Current | 70.4% | 84.00 | 49.00 | 49.00 | 49.00 | - |
Shareholder's Equity | -23.9% | 150 | 197 | 11.00 | 84.00 | 146 |
Retained Earnings | -8.0% | -1,039 | -962 | -876 | -795 | -724 |
Additional Paid-In Capital | 2.6% | 1,190 | 1,160 | 888 | 880 | 871 |
Shares Outstanding | 1.0% | 18.00 | 18.00 | 17.00 | 17.00 | 17.00 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
Cashflow From Operations | -15.2% | -259 | -224 | -214 | -200 | -190 |
Share Based Compensation | 11.9% | 35.00 | 32.00 | 30.00 | 28.00 | 28.00 |
Cashflow From Investing | -117.5% | -36.10 | 207 | 156 | 131 | 84.00 |
Cashflow From Financing | 16.8% | 366 | 313 | 69.00 | 90.00 | 104 |
95.4%
89.2%
59.2%
Y-axis is the maximum loss one would have experienced if Madrigal Pharmaceuticals was unfortunately bought at previous high price.
0.8%
56.4%
1.1%
34.1%
FIve years rolling returns for Madrigal Pharmaceuticals.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-05-26 | ProShare Advisors LLC | reduced | -9.73 | -218,464 | 667,669 | -% |
2023-05-25 | Legato Capital Management LLC | new | - | 488,154 | 488,154 | 0.09% |
2023-05-24 | Verity Asset Management, Inc. | added | 44.23 | 60,455 | 357,091 | 0.21% |
2023-05-23 | Capital Impact Advisors, LLC | added | 17.85 | -11,658 | 700,616 | 0.86% |
2023-05-22 | AMERIPRISE FINANCIAL INC | reduced | -8.39 | -97,397 | 317,603 | -% |
2023-05-18 | JPMORGAN CHASE & CO | reduced | -1.81 | -2,850,000 | 12,947,000 | -% |
2023-05-18 | NEW YORK STATE COMMON RETIREMENT FUND | reduced | -19.02 | -2,033,000 | 4,240,000 | 0.01% |
2023-05-16 | Hudson Bay Capital Management LP | new | - | 6,226,080 | 6,226,080 | 0.03% |
2023-05-16 | JANE STREET GROUP, LLC | added | 161 | 15,112,200 | 27,906,400 | 0.01% |
2023-05-16 | FRED ALGER MANAGEMENT, LLC | added | 29.44 | 376,167 | 5,055,000 | 0.03% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 14, 2023 | armistice capital, llc | 1.21% | 208,000 | SC 13G/A | |
Feb 14, 2023 | deep track capital, lp | 0% | 0 | SC 13G/A | |
Feb 14, 2023 | baker bros. advisors lp | 9.0% | 1,545,113 | SC 13G/A | |
Feb 14, 2023 | avoro capital advisors llc | 9.7% | 1,660,000 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 7.40% | 1,266,375 | SC 13G/A | |
Feb 06, 2023 | wellington management group llp | 0.19% | 31,830 | SC 13G/A | |
Feb 02, 2023 | state street corp | 7.37% | 1,260,993 | SC 13G | |
Feb 01, 2023 | blackrock inc. | 5.8% | 986,572 | SC 13G/A | |
May 19, 2022 | deep track capital, lp | 5.37% | 917,825 | SC 13G | |
Feb 15, 2022 | armistice capital, llc | 6.6% | 1,124,000 | SC 13G |
Date Filed | Form Type | Document | |
---|---|---|---|
May 09, 2023 | 8-K | Current Report | |
May 09, 2023 | 8-K | Current Report | |
May 09, 2023 | 424B5 | Prospectus Filed | |
May 09, 2023 | 10-Q | Quarterly Report | |
May 01, 2023 | DEFA14A | DEFA14A | |
May 01, 2023 | DEF 14A | DEF 14A | |
Apr 21, 2023 | PRE 14A | PRE 14A | |
Mar 03, 2023 | 10-K/A | Annual Report | |
Mar 02, 2023 | 4 | Insider Trading | |
Feb 23, 2023 | 8-K | Current Report |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-03-01 | Waltermire Robert E. | acquired | 439,600 | 87.92 | 5,000 | senior vp, chief pharma dev. |
2023-03-01 | Waltermire Robert E. | sold | -1,372,080 | 274 | -5,000 | senior vp, chief pharma dev. |
2023-02-28 | Waltermire Robert E. | acquired | 439,600 | 87.92 | 5,000 | senior vp, chief pharma dev. |
2023-02-28 | Waltermire Robert E. | sold | -1,360,360 | 272 | -5,000 | senior vp, chief pharma dev. |
2023-01-17 | Levy Richard S | acquired | 2,316,840 | 103 | 22,489 | - |
2023-01-17 | Levy Richard S | sold | -6,592,690 | 293 | -22,489 | - |
2023-01-16 | Howarth Alex G. | acquired | - | - | 15,001 | chief financial officer |
2023-01-16 | FRIEDMAN PAUL A | acquired | - | - | 26,668 | chief executive officer |
2023-01-16 | Taub Rebecca | acquired | - | - | 20,001 | pres., r&d, and cmo |
2023-01-16 | Lynch Brian Joseph | acquired | - | - | 15,001 | svp and general counsel |
Condensed Consolidated Statements Of Operations - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2023 | Mar. 31, 2022 | |
Revenues: | ||
Total revenues | ||
Operating expenses: | ||
Research and development | 62,154 | 47,929 |
General and administrative | 16,182 | 9,658 |
Total operating expenses | 78,336 | 57,587 |
Loss from operations | (78,336) | (57,587) |
Interest income | 3,776 | 69 |
Interest expense | (2,336) | 0 |
Net loss | $ (76,896) | $ (57,518) |
Net loss per common share: | ||
Basic net loss per common share | $ (4.23) | $ (3.36) |
Diluted net loss per common share | $ (4.23) | $ (3.36) |
Basic weighted average number of common shares outstanding | 18,187,924 | 17,103,395 |
Diluted weighted average number of common shares outstanding | 18,187,924 | 17,103,395 |
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 113,308 | $ 331,549 |
Marketable securities | 216,169 | 27,225 |
Prepaid expenses and other current assets | 1,807 | 2,595 |
Total current assets | 331,284 | 361,369 |
Property and equipment, net | 512 | 601 |
Right-of-use asset | 653 | 602 |
Total assets | 332,449 | 362,572 |
Current liabilities: | ||
Accounts payable | 12,128 | 23,831 |
Accrued expenses | 85,567 | 91,461 |
Lease liability | 653 | 602 |
Total current liabilities | 98,348 | 115,894 |
Long term liabilities: | ||
Loan payable, net of discount | 83,965 | 49,289 |
Total long term liabilities | 83,965 | 49,289 |
Total liabilities | 182,313 | 165,183 |
Stockholders' equity: | ||
Preferred stock, par value $0.0001 per share authorized: 5,000,000 shares at March 31, 2023 and December 31, 2022; 2,369,797 and 2,369,797 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively | ||
Common stock, par value $0.0001 per share authorized: 200,000,000 at March 31, 2023 and December 31, 2022; 18,283,074 and 18,102,523 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively | 2 | 2 |
Additional paid-in-capital | 1,189,776 | 1,160,079 |
Accumulated other comprehensive loss | (86) | (32) |
Accumulated deficit | (1,039,556) | (962,660) |
Total stockholders' equity | 150,136 | 197,389 |
Total liabilities and stockholders' equity | $ 332,449 | $ 362,572 |